{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:42:38Z","timestamp":1653813758495},"reference-count":6,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,4,20]]},"DOI":"10.1200\/jco.20.00042","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T19:59:17Z","timestamp":1583956757000},"page":"1368-1369","update-policy":"http:\/\/dx.doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Reply to N. Biran et al"],"prefix":"10.1200","volume":"38","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[{"name":"Sagar Lonial, MD, Madhav V. Dhodapkar, MBBS, MD, Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA; and S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Sagar Lonial, MD, Madhav V. Dhodapkar, MBBS, MD, Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA; and S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Sagar Lonial, MD, Madhav V. Dhodapkar, MBBS, MD, Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA; and S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02972"},{"key":"b2","author":"Lonial S","journal-title":"J Clin Oncol"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30124-3"},{"key":"b6","doi-asserted-by":"crossref","unstructured":"Mateos M, Martinez-Lopez J, Otero PR, et al: Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): Carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Presented at the American Society of Hematology Annual Meeting, Orlando, FL, December 7-10, 2019","DOI":"10.1182\/blood-2019-125204"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:05:47Z","timestamp":1653811547000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.00042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,4,20]]}},"alternative-id":["10.1200\/JCO.20.00042"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.00042","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"2020-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}